Free Trial

Taysha Gene Therapies (TSHA) to Release Quarterly Earnings on Thursday

Taysha Gene Therapies logo with Medical background

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) will likely be posting its Q1 2025 quarterly earnings results before the market opens on Thursday, May 15th. Analysts expect Taysha Gene Therapies to post earnings of ($0.08) per share and revenue of $1.48 million for the quarter.

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last issued its quarterly earnings results on Wednesday, February 26th. The company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.08) by $0.01. The company had revenue of $2.02 million for the quarter, compared to the consensus estimate of $2.05 million. Taysha Gene Therapies had a negative net margin of 229.67% and a negative return on equity of 106.36%. On average, analysts expect Taysha Gene Therapies to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Taysha Gene Therapies Stock Up 1.4 %

NASDAQ TSHA traded up $0.03 during midday trading on Friday, hitting $2.13. 2,133,951 shares of the company traded hands, compared to its average volume of 2,815,250. Taysha Gene Therapies has a 52 week low of $1.05 and a 52 week high of $4.32. The company's 50-day simple moving average is $1.65 and its 200-day simple moving average is $1.81. The company has a debt-to-equity ratio of 0.48, a current ratio of 5.51 and a quick ratio of 5.51. The company has a market cap of $436.77 million, a PE ratio of 3.38 and a beta of 0.90.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the stock. Needham & Company LLC reaffirmed a "buy" rating and set a $6.00 price objective on shares of Taysha Gene Therapies in a research note on Thursday, April 10th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $7.00 target price on shares of Taysha Gene Therapies in a research note on Monday, April 28th. JMP Securities reaffirmed a "market outperform" rating and issued a $5.00 target price on shares of Taysha Gene Therapies in a research note on Monday, April 28th. Finally, Chardan Capital reissued a "buy" rating and set a $7.00 target price on shares of Taysha Gene Therapies in a research note on Wednesday, February 26th. Eight analysts have rated the stock with a buy rating, According to MarketBeat, Taysha Gene Therapies presently has an average rating of "Buy" and an average price target of $6.63.

Check Out Our Latest Stock Report on TSHA

Taysha Gene Therapies Company Profile

(Get Free Report)

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.

Featured Stories

Earnings History for Taysha Gene Therapies (NASDAQ:TSHA)

Should You Invest $1,000 in Taysha Gene Therapies Right Now?

Before you consider Taysha Gene Therapies, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Taysha Gene Therapies wasn't on the list.

While Taysha Gene Therapies currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

NVIDIA Earnings Preview: HUGE Stock Move Ahead
These 5 Small Stocks Could Deliver Huge Returns
ACT FAST! Congress Is POURING Into This Stock

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines